Skip to content

Financial Information

This section of the Karyopharm Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Karyopharm Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQKPTI
Beta1.16
Shares Outstanding73.5M
Average Volume (10 days)1.3M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($2.84)
Sales (TTM)$1.13
Book Value (MRQ)$1.77
Cash Flow (TTM)($2.42)
Cash (MRQ)$4.05

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy7
 
Buy1
 
Hold1
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Christopher Brett Primiano
EVP, CBO, GC & Secretary
(10,054)
Sell
Sep 8, 2020
Michael G. Kauffman
Director, Chief Executive Officer
(1,477)
Sell
Aug 17, 2020
Sharon Shacham
President & CSO
(1,477)
Sell
Aug 17, 2020
Michael G. Kauffman
Director, Chief Executive Officer
(7,500)
Sell
Jul 15, 2020
Sharon Shacham
President & CSO
(7,500)
Sell
Jul 15, 2020

Recent SEC Filings

Company Events
Sep 25, 2020
Insider Buy/Sell
Sep 10, 2020
Insider Buy/Sell
Aug 31, 2020
New Insider
Aug 31, 2020
Company Events
Aug 31, 2020
I agree to the storing and processing of my personal data by Karyopharm as described in the Privacy Policy and to the Terms of Use . I agree to receive communications from Karyopharm and understand that I can unsubscribe at any time.